共 104 条
[1]
Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., Et al., Heart disease and stroke statistics—2017 update: a report from the American Heart Association, Circulation, 135, (2017)
[2]
Arena R., Myers J., Aslam S.S., Varughese E.B., Peberdy M.A., Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison, Am Heart J, 147, pp. 354-360, (2004)
[3]
Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Et al., Outcome of heart failure with preserved ejection fraction in a population-based study, New England Journal of Medicine, 355, pp. 260-269, (2006)
[4]
Chioncel O., Lainscak M., Seferovic P.M., Anker S.D., Crespo-Leiro M.G., Harjola V.P., Et al., Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, (2017)
[5]
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis, European Heart Journal, 33, pp. 1750-1757, (2012)
[6]
Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Et al., Irbesartan in patients with heart failure and preserved ejection fraction, New England Journal of Medicine, 359, pp. 2456-2467, (2008)
[7]
Kitzman D.W., Hundley W.G., Brubaker P.H., Morgan T.M., Moore J.B., Stewart K.P., Et al., A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility, Circ Heart Fail, 3, pp. 477-485, (2010)
[8]
Edelmann F., Wachter R., Schmidt A.G., Kraigher-Krainer E., Colantonio C., Kamke W., Et al., Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial, JAMA, 309, pp. 781-791, (2013)
[9]
Kinugawa S., Tsutsui H., Ide T., Nakamura R., Arimura K., Egashira K., Et al., Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes, Cardiovasc Res, 43, pp. 157-164, (1999)
[10]
Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, pp. 2338-2345, (2006)